Fecal microbiota
From Wikipedia, the free encyclopedia
Fecal microbiota, sold under the brand name, Rebyota is used for the prevention of recurrence of Clostridioides difficile infection.[1][4]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Rebyota |
Other names | RBX2660, fecal microbiota, live - jslm |
License data | |
Routes of administration | Rectal |
ATC code |
|
Legal status | |
Legal status |
Close
The most commonly reported adverse reactions include abdominal pain, diarrhea, abdominal distention, flatulence, and nausea.[1]
Fecal microbiota is prepared from stool donated by qualified individuals.[4] The donors and the donated stool are tested for a panel of transmissible pathogens.[4] Fecal microbiota is the first fecal microbiota product approved by the US Food and Drug Administration (FDA).[4] Fecal microbiota was approved for medical use in the United States in November 2022.[4]